Alto Neuroscience, Inc. (ANRO) earnings date
Mar 18, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 40% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 16 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Nov 10, 2026 | after close | 41 | 8-K |
| Q2 FY2026 | Wed, Aug 12, 2026 | after close | 43 | 8-K |
| Q1 FY2026 | Wed, May 13, 2026 | before open | 43 | 8-K |
| Q4 FY2025 | Mon, Mar 16, 2026 | before open | 75 | 8-K |
| Q3 FY2025 | Wed, Nov 12, 2025 | before open | 43 | 8-K |
| Q2 FY2025 | Wed, Aug 13, 2025 | after close | 44 | 8-K |
| Q1 FY2025 | Wed, May 14, 2025 | after close | 44 | 8-K |
| Q4 FY2024 | Thu, Mar 20, 2025 | after close | 79 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights – PACE-1 trial of ALTO-207 in treatment-resistant depression (TRD) on track; topline data in 2H 2027 – – Phase 1 study results on the modified-release formulation of ALTO-207 and blinded PACE-1 safety data expected by early 2027; data expected to inform Phase 3 planning – – Strengthened balance sheet and extended cash runway with $100 million financing; cash position of $319.8 million expected to fund planned operations through 2030 – MOUNTAIN VIEW, Calif., November 10, 2026 – (" exhibit |
| Q3 FY2026 | "Topline data are expected in 2H 2027." exhibit |
| Q3 FY2026 | "PACE-2 (Phase 3, adjunctive TRD): Alto remains on track to initiate the trial in early 2027, pending alignment with the FDA on trial design." exhibit |
| Q3 FY2026 | "Initiation is expected in 2H 2027, pending FDA alignment." exhibit |
| Q3 FY2026 | "Alto expects to report the outcome of the FDA interaction and the Phase 1 data, along with blinded PACE-1 safety results in late 2026 or early 2027 following FDA feedback." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights – ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoing potentially registrational Phase 2b trial; topline Phase 2b data on track for 2H 2027 – – Independent investigator-led study results published in Nature Medicine reinforce the dopaminergic mechanism underlying ALTO-207, demonstrating significant effects on anhedonia (Hedges' g=0.62, p=0.006) – – Approximatel" exhibit |
| Q2 FY2026 | "With enrollment in our potentially registrational Phase 2b trial tracking as planned and pro forma cash of approximately $338 million, we are now positioned to pursue ALTO-207 in both the adjunctive and monotherapy settings, broadening the potential label and the commercial opportunity, with expected runway through 2030.”" exhibit |
| Q2 FY2026 | "PACE-1 Trial (Phase 2b adjunctive TRD trial): Enrollment in the ongoing, potentially registrational, Phase 2b trial of ALTO-207 as an adjunctive treatment in approximately 178 adults with TRD is on track with topline data expected in 2H 2027." exhibit |
| Q2 FY2026 | "PACE-2 Trial (Phase 3 adjunctive TRD trial) : Alto remains on track to initiate its Phase 3 trial of ALTO-207 as adjunctive treatment in TRD by early 2027, following alignment with the FDA on the planned trial design." exhibit |
| Q2 FY2026 | "Alto expects to initiate this trial in the second half of 2027 pending alignment with the FDA." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ANRO
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ANRO
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ANRO/"><img src="https://veritasdata.dev/embed/ANRO.svg" alt="ANRO earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ANRO/)
Script
<script async src="https://veritasdata.dev/embed/ANRO.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ANRO"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.